COMMUNIQUÉS West-GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2025
30/09/2025
Aggregated presentation by day and by market Statement of transactions in own shares from September 22nd to September 26th 2025 Name of the issue Identity code of the issuer (Legal Entity Identifier) Day of the [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 39 - 2025
30/09/2025
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 22 Septembre au 26 Septembre 2025 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la [...]
Clinical Match Me Announces Strategic Partnership with NPACE
30/09/2025
Clients to Benefit from Exclusive Discounts and Enhanced Educational Opportunities San Juan, PR, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Clinical Match Me , a transformative force in Nurse Practitioner education, NP [...]
Sequana Medical’s alfapump® System Featured in Presentation at 2025 Portal Intervention Symposium
30/09/2025
Dr. Rahul Patel of Icahn School of Medicine at Mount Sinai presented “alfapump®: Totally Implantable Peritoneal Drain Pump with Urinary Bladder Drainage” Ghent, Belgium – September 30, 2025 – Sequana Medical NV ( [...]
Major Wellbeing Organization Selects Aino’s SaaS Platform
30/09/2025
Aino Health AB (publ) has signed an agreement—facilitated through its occupational health collaboration partner Työterveys Aalto Occupational Health Care —with a leading wellbeing sector organization, covering 11,000 [...]
BEYOND IMMORTALITY: European Wellness Biomedical Group Charts Longevity Through Cell Regeneration Over Organ Transplant
30/09/2025
From hot-mic whispers of World Leaders to groundbreaking science, Prof. Mike Chan reveals why cellular regeneration — not organ swaps, holds the key to extending human healthspan and lifespan. A Whisper in Beijing [...]
Change in Board’s Composition
30/09/2025
Press Release Paris – September 30, 2025 - EUROAPI today announces that, in line with best governance’s practices, and following his appointment as Recipharm’s Chief Financial Officer, effective October 1 st , 2025, [...]
Evolution de la composition du Conseil d’administration
30/09/2025
Communiqué de presse Paris - Le 30 septembre 2025 - EUROAPI annonce aujourd’hui que conformément aux bonnes pratiques de gouvernance et à la suite de sa nomination en tant que directeur financier de Recipharm à compter [...]
AiM Medical Robotics Secures $8.1 Million Series A Financing to Transform Neurosurgery with MRI-Compatible Surgical Robotics
30/09/2025
— Financing round led by IQ Capital and 1540 Ventures accelerates path to first-in-human trials for groundbreaking robotic neurosurgical platform — WORCESTER, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- AiM Medical [...]
PETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF NOTE CONVERSION AGREEMENTS TO EXTINGUISH OVER TWO MILLION DOLLARS OF OUTSTANDING DEBT
30/09/2025
MINNEAPOLIS, Sept. 30, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) and its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively "PetVivo" or the “Company”) an emerging [...]
Total number of shares and voting rights in Zealand Pharma as of September 30, 2025
30/09/2025
Company announcement – No. 21 / 2025 Total number of shares and voting rights in Zealand Pharma as of September 30, 2025 Copenhagen, Denmark, September 30, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) ( [...]
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
30/09/2025
New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte’s Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates SAN CARLOS, Calif., Sept. 30, 2025 ( [...]
SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update
30/09/2025
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for [...]
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
30/09/2025
BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Branded Legacy, Inc. Announces Provisional Patent Filing by BioLegacy for Disruptive Air-Driven Intranasal Platform Targeting Multi-Billion-Dollar Global Therapeutics Market
30/09/2025
Revolutionary platform aims to make life-saving overdose reversal therapies more affordable, accessible, and effective worldwide VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy [...]
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial
30/09/2025
Publication title: “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease Patients” [...]
Cannabix Technologies Announces First Sale of BreathLogix Alcohol Screening Device to Maritime Market
30/09/2025
VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is [...]
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
30/09/2025
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression-Free Survival and Overall Survival FLORHAM PARK, N.J., Sept. 30, 2025 ( [...]
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering
30/09/2025
SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]

Pages